Icon Advisers Inc. Co. Invests $1.26 Million in Insulet Corporation $PODD

Icon Advisers Inc. Co. acquired a new stake in Insulet Corporation (NASDAQ:PODD) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,000 shares of the medical instruments supplier’s stock, valued at approximately $1,259,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp grew its position in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after acquiring an additional 65,317 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares in the last quarter. Invesco Ltd. raised its position in shares of Insulet by 10.5% during the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after acquiring an additional 141,167 shares in the last quarter. Norges Bank bought a new position in Insulet during the fourth quarter worth $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Insulet by 3.8% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock worth $229,131,000 after purchasing an additional 29,690 shares during the last quarter.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was acquired at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the transaction, the director directly owned 9,041 shares of the company’s stock, valued at $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.36% of the stock is currently owned by corporate insiders.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Negative Sentiment: Multiple law firms announced or reminded investors about a recently filed securities fraud class action against Insulet, with claims tied to alleged misstatements about Omnipod safety and manufacturing practices. The filings cite two recalls affecting millions of pods and say the issues may have hurt investors who bought shares during the class period. Article Title
• Negative Sentiment: The lawsuit coverage suggests investors are still digesting the fallout from prior recalls and related stock declines, and firms are encouraging shareholders to seek lead-plaintiff roles before the August 31 deadline. Article Title
• Neutral Sentiment: One item noted that analysts still expect double-digit earnings growth ahead of Insulet’s next quarterly report, which provides a potential longer-term offset to the legal headlines. Article Title

Wall Street Analyst Weigh In

PODD has been the subject of a number of research reports. Oppenheimer decreased their price objective on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Truist Financial reduced their price target on shares of Insulet from $219.00 to $210.00 and set a “buy” rating on the stock in a research report on Monday, July 13th. BTIG Research decreased their price target on shares of Insulet from $260.00 to $235.00 and set a “buy” rating for the company in a report on Tuesday, May 26th. Evercore set a $180.00 price objective on shares of Insulet in a research report on Monday, July 6th. Finally, Leerink Partners lowered their price objective on shares of Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $235.25.

Insulet Trading Down 2.9%

Insulet stock opened at $158.93 on Thursday. The firm has a market cap of $11.01 billion, a price-to-earnings ratio of 36.96, a price-to-earnings-growth ratio of 1.14 and a beta of 1.11. Insulet Corporation has a 1 year low of $138.79 and a 1 year high of $354.88. The firm’s 50 day moving average price is $153.58 and its two-hundred day moving average price is $203.76. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts predict that Insulet Corporation will post 6.45 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.